Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous bone marrow cell concentrate, commonly referred to as BMAC, is a biologic therapy obtained by aspirating bone marrow from the patient's iliac crest or other bone. The aspirate is then processed—most often by centrifugation—to concentrate the nucleated cell fraction, including mesenchymal stem cells, hematopoietic stem cells, platelets, growth factors, and cytokines. BMAC is injected back into injured or degenerative tissues to promote healing, regeneration, and modulation of inflammation. Its mechanism is believed to include both direct tissue regeneration by stem cell differentiation and paracrine signaling through growth factors and cytokines[1][4][7][9]. BMAC is not manipulated beyond concentration and is not cultured or expanded, which keeps it within FDA regulatory guidelines for minimal manipulation[1][3][4][9]. Indications include osteoarthritis, cartilage injury, tendon injury, bone fractures, osteonecrosis, and wound healing[2][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous bone marrow cell concentrate.